AAP
NRIX icon

Arax Advisory Partners’s Nurix Therapeutics NRIX Stock Holding History

Arax Advisory Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44
Closed -$836 – 4165
2025
Q4 		$836 Sell
44
-69
-61% -$991 ﹤0.01% 3525
2025
Q3 		$1.04K Buy
+113
New +$1.17K ﹤0.01% 3249
2025
Q1 		– Sell
-130
Closed -$2.45K – 2925
2024
Q4 		$2.45K Hold
130
– – ﹤0.01% 1961
2024
Q3 		$2.92K Hold
130
– – ﹤0.01% 1919
2024
Q2 		$2.71K Buy
+130
New +$2.02K ﹤0.01% 1854

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Arax Advisory Partners's NRIX Position: Q1 2026 in Review

Arax Advisory Partners sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 44 shares — an estimated $836 sold.

Arax Advisory Partners first reported a position in NRIX in Q2 2024 and held it in 5 quarters. The position peaked at $2.92K in Q3 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Arax Advisory Partners reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 44 Nurix Therapeutics shares in Q1 2026, an estimated $836.
  • Arax Advisory Partners first reported a position in Nurix Therapeutics in Q2 2024 and held it in 5 quarters.
  • Arax Advisory Partners's Nurix Therapeutics position peaked at $2.92K in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.